ArticleNeuro-oncology2020
Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.
Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Proton beam therapy indications in the Kingdom of Saudi Arabia: A SARO clinical practice guideline.Saudi medical journal · 2025Guideline
- Proton beam and carbon ion radiotherapy in skull base chordoma: a systematic review, meta-analysis and meta-regression with trial sequential analysis.Neurosurgical review · 2024Pooled it
- A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy.Cancer medicine · 2024Pooled it
- The Clinical outcomes following pencil beam scanning proton therapy for skull base chordoma and chondrosarcoma: a single-institution experience.Acta oncologica (Stockholm, Sweden) · 2026Article
- From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical Implications.Cells · 2026Review
- Quantitative Susceptibility Mapping in Skull Base Chordoma: In Silico Analysis and In Vivo Application Towards Indirect Hypoxia Assessment.Magnetic resonance in medicine · 2026Article
- Cervical Vertebral Body Implant Modification Accommodating Vertebral Artery Aneurysm Clips: A Case Report.Cureus · 2026Article
- Enhancing dose conformity in head and neck intensity-modulated proton therapy using a novel dynamic multi-leaf collimator strategy.Medical physics · 2026Article
- Evaluating the technical feasibility of biology-guided dose painting in proton therapy.Physics and imaging in radiation oncology · 2025Article
- Endoscopic Endonasal Approach for Clival Chordomas in Elderly Patients: Clinical Characteristics, Patient Outcome, and Recurrence Rate.Journal of neurological surgery. Part B, Skull base · 2024Article
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- The Clinical Outcomes of Cervical Spine Chordoma: A Nationwide Multicenter Retrospective Study.Neurospine · 2024Article
- Review
- How proton therapy fits into the management of adult intracranial tumors.Neuro-oncology · 2024Review
- Article
- Risk Factors for Radiation Necrosis and Local Recurrence after Proton Beam Therapy for Skull Base Chordoma or Chondrosarcoma.Cancers · 2023Article
- Review
- Current topics and management of head and neck sarcomas.Japanese journal of clinical oncology · 2023Review
- Critical Appraisal of Proton Therapy for Patients with Central Nervous System (CNS) Malignancies.Current treatment options in oncology · 2023Review
- Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience.Cancers · 2023Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
23 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to evaluate results in terms of local control (LC), overall survival (OS), and toxicity profile and to better identify factors influencing clinical outcome of skull base chordoma treated with proton therapy (PT) and carbon ion radiotherapy (CIRT).
methodsWe prospectively collected and analyzed data of 135 patients treated between November 2011 and December 2018. Total prescription dose in the PT group (70 patients) and CIRT group (65 patients) was 74 Gy relative biological effectiveness (RBE) delivered in 37 fractions and 70.4 Gy(RBE) delivered in 16 fractions, respectively (CIRT in unfavorable patients). LC and OS were evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed, to identify prognostic factors on clinical outcomes.
resultsAfter a median follow-up of 44 (range, 6-87) months, 14 (21%) and 8 (11%) local failures were observed in CIRT and PT group, respectively. Five-year LC rate was 71% in CIRT cohort and 84% in PT cohort. The estimated 5-year OS rate in the CIRT and PT group was 82% and 83%, respectively. On multivariate analysis, gross tumor volume (GTV), optic pathways, and/or brainstem compression and dose coverage are independent prognostic factors of local failure risk. High rate toxicity grade ≥3 was reported in 11% of patients.
conclusionsParticle radiotherapy is an effective treatment for skull base chordoma with acceptable late toxicity. GTV, optic pathways, and/or brainstem compression and target coverage were independent prognostic factors for LC. KEY POINTS: • Proton and carbon ion therapy are effective and safe in skull base chordoma.• Prognostic factors are GTV, organs at risk compression, and dose coverage.• Dual particle therapy and customized strategy was adopted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.